Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis

Spiegel B M R, Chen K, Chiou C F, Robbins S, Younossi Z M

**Record Status**
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

**Bibliographic details**

**PubMedID**
16234051

**Indexing Status**
Subject indexing assigned by NLM

**MeSH**
Anemia /chemically induced /drug therapy /economics; Antiviral Agents /administration & dosage /adverse effects; Cohort Studies; Cost-Benefit Analysis; Darbepoetin alfa; Erythropoietin /analogs & derivatives /economics /therapeutic use; Hepatitis C, Chronic /complications /drug therapy; Humans; Interferon-alpha /administration & dosage; Liver Cirrhosis /economics /etiology; Polyethylene Glycols /administration & dosage; Recombinant Proteins; Ribavirin /administration & dosage /adverse effects; Transaminases /blood; Treatment Outcome

**AccessionNumber**
22005001580

**Date bibliographic record published**
13/12/2005